Catron Tom D, Smallfield George B, Kang Le, Sterling Richard K, Siddiqui Mohammad S
Tinsley Harrison Internal Medicine Residency Training Program, University of Alabama at Birmingham, 1720 2nd Ave South, Birmingham, AL, 35233, USA.
Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, VCU Medical Center, 1200 E Marshall Street, Richmond, VA, 23298, USA.
Dig Dis Sci. 2017 Nov;62(11):3091-3099. doi: 10.1007/s10620-017-4671-2. Epub 2017 Jul 12.
Gastric varices (GV) have higher rates of morbidity and mortality from hemorrhage than esophageal varices. Several studies have shown the safety and efficacy of cyanoacrylate (CA) injection for acute gastric variceal hemorrhage. We report data from our experience with CA injection for GV before and after routine use of post-injection audible Doppler assessment (ADA) for GV obturation and describe long-term outcomes after this therapy.
We retrospectively identified patients who had documented GV, underwent CA injection, and had at least 2 weeks of follow-up. We recorded and analyzed the survival and rebleeding rates with patient demographics, clinical data, and endoscopy findings between two groups of patients who were categorized by CA injection prior to and after inception of the ADA technique.
Seventy-one patients were identified with 16 patients analyzed in a group where ADA was not used (Pre-ADA) and 55 analyzed where ADA was used (Post-ADA). No rebleeding events were observed within 1 week of initial CA injection. No embolic events were reported after any initial CA injection within 4 weeks. The rate of bleed-free survival at 1 year was 69.6% in the Pre-ADA group and 85.8% in the Post-ADA without statistical significance. The all-cause 1-year mortality was 13.8% in the Pre-ADA group and 10.7% in the Post-ADA group without statistical significance.
ADA of CA-injected GV does not appear to significantly affect adverse events or clinical outcomes; however, our findings are limited by small sample size and cohort proportions allowing for significant type II statistical error. Further prospective investigation is required to determine the impact of ADA on clinical outcomes after GV obturation.
胃静脉曲张(GV)出血导致的发病率和死亡率高于食管静脉曲张。多项研究表明,氰基丙烯酸酯(CA)注射治疗急性胃静脉曲张出血具有安全性和有效性。我们报告了在常规使用注射后可听多普勒评估(ADA)以闭塞GV之前和之后,CA注射治疗GV的经验数据,并描述了该治疗后的长期结果。
我们回顾性地确定了有记录的GV、接受CA注射且至少随访2周的患者。我们记录并分析了两组患者的生存和再出血率,这两组患者根据ADA技术开始之前和之后进行CA注射进行分类,同时记录了患者的人口统计学、临床数据和内镜检查结果。
共确定71例患者,其中16例在未使用ADA的组中进行分析(ADA前),55例在使用ADA的组中进行分析(ADA后)。首次CA注射后1周内未观察到再出血事件。在4周内任何首次CA注射后均未报告栓塞事件。ADA前组1年无出血生存率为69.6%,ADA后组为85.8%,无统计学意义。ADA前组全因1年死亡率为13.8%,ADA后组为10.7%,无统计学意义。
对注射CA的GV进行ADA似乎不会显著影响不良事件或临床结果;然而,我们的研究结果受样本量小和队列比例的限制,存在显著的II型统计误差。需要进一步的前瞻性研究来确定ADA对GV闭塞后临床结果的影响。